Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Veracyte Earnings Call: Key Takeaways

Veracyte delivered a Q3 revenue beat but significantly lowered Decipher prostate volume expectations, signaling a transition from outsized guideline-driven growth to a normalized, more competitive market environment.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthTotal revenue 15%; Testing revenue 15%; Afirma 19%; Decipher prostate 12%.
Mgmt ConfidenceConfident in long-term 80% share but resetting near-term volume expectations lower.
Demand VisibilityDecipher volume 1,000 tests lower than expected; Afirma sequential Q3 record.
Margin TrendsNon-GAAP Gross Margin 73.7%; Adjusted EBITDA 27.2% exceeding 25% target.
Op. LeverageMoving software costs to R&D; 2027 EBITDA guided lower at 22%.
Pricing PowerNormalized ASP rose 2% to $2,900; sustained pricing gains from operations.
Vol vs PriceVolume-led 15% growth; ASP contributed 1% including prior period collections.
Segment GrowthAfirma outperformed; Decipher prostate volume growth moderated to 12% year-over-year.
New ClientsServed one millionth patient; adding new and reactivated physicians in October.
Capex & Debt$150M cash payment for Convergent Genomics; $100M share repurchase program authorized.
RegulatoryMedicare reimbursement secured for ProSigna in post-menopausal women with 0-3 nodes.
CommentaryResetting annual Decipher volume growth to 12,000-15,000 tests as a floor.
New LaunchesLaunched ProSigna LDT for breast cancer and TrueMRD for bladder cancer.

Growth

Q3 revenue grew 15% to $151.8M; Afirma grew 19%, while Decipher prostate grew 12%.

Outlook

FY2027 revenue growth guided to mid-single digits; Decipher volume floor set at 12,000.

Risks

Management pivoted on Decipher volume shortfall, citing 'temporal acceleration' and competition from digital pathology AI.

Source

The company's earnings call, NASDAQ: VCYT, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Veracyte, Inc.: key numbers

Share price
$24.01Close, Nov 16
Market cap
$1.94B
Shares outstanding
80.7MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Veracyte, Inc.

All →
4:10 PM ET 8-K
Financial Results

Veracyte Financial Results

Veracyte reported Q3 2026 financial results with total revenue growing 15% year-over-year to $151.8 million, driven by strong performance in its Afirma and Decipher Prostate tests. The company also announced that its Board of Directors authorized a new $100 million share repurchase program to be executed over a one-year period.

“We delivered solid third quarter results supported by strong profitability and cash generation. Afirma outperformed, while Decipher Prostate volume was below our expectations. We remain confident in the long-term outlook of our business and expect a number of evidence-based catalysts to support growth in our core franchises while also advancing our breast and bladder strategies. As we execute on these opportunities, our differentiated financial profile enables us to continue investing in the business to drive long-term growth.”

Marc Stapley, chief executive officer of Veracyte
4:06 PM ET Form 4
Insider Selling

Veracyte Insider Jens Holstein Sells $728K of Stock

Jens Holstein sold 15,000 shares of Veracyte, Inc. at $47.00 to $50.00 a share (average $48.50) in 2 transactions, worth $728K in total between Sep 24, 2026 and Oct 27, 2026. Shares held after the trade: 27,471 (-21.4%).

Value
$728K
Shares
15,000
Average price
$48.50
Holding change
-21.4%
Trade date
Sep 24, 2026 to Oct 27, 2026
4:06 PM ET Form 4
Insider Selling

Veracyte Insider Karin Eastham Sells $743K of Stock

Karin Eastham sold 14,850 shares of Veracyte, Inc. at $50.00 a share, worth $743K in total on Oct 27, 2026. Shares held after the trade: 10,247 (-59.2%).

Value
$743K
Shares
14,850
Price
$50.00
Holding change
-59.2%
Trade date
Oct 27, 2026
4:11 PM ET Form 4
Insider Selling

Veracyte Insider Muna Bhanji Sells $81.5K of Stock

Muna Bhanji sold 1,864 shares of Veracyte, Inc. at $43.70 a share, worth $81.5K in total on Oct 19, 2026. Shares held after the trade: 40,854 (-4.4%).

Value
$81.5K
Shares
1,864
Price
$43.70
Holding change
-4.4%
Trade date
Oct 19, 2026
4:09 PM ET Form 4
Insider Selling

Veracyte Insider Jens Holstein Sells $205K of Stock

Jens Holstein sold 5,000 shares of Veracyte, Inc. at $40.95 a share, worth $205K in total on Sep 14, 2026. Shares held after the trade: 27,471 (-15.4%).

Value
$205K
Shares
5,000
Price
$40.95
Holding change
-15.4%
Trade date
Sep 14, 2026
4:08 PM ET 8-K
M&A Deal

Veracyte Signs $150M M&A Deal with Convergent Genomics Inc.

Veracyte completed the acquisition of Convergent Genomics, a genomic diagnostics company focused on bladder cancer, for $150 million in upfront cash plus up to $30 million in milestone-based payments. The deal adds the UroAmp urinary tumor DNA (utDNA) technology to Veracyte's urology portfolio, with a commercial launch expected in late 2028.

Value
$150M
Counterparty
Convergent Genomics Inc.

“UroAmp brings a differentiated urine-based platform that is especially well suited to non-muscle-invasive disease. Together with our Decipher Bladder and TrueMRD tests, this acquisition strengthens Veracyte’s ability to deliver complementary insights from urine, tissue, and blood to help guide care across the bladder cancer continuum.”

Marc Stapley, Veracyte’s chief executive officer

“We believe this combination can help accelerate the development of new tools that give physicians greater confidence in treatment and monitoring decisions and can ultimately improve care for people living with bladder cancer.”

Brian Slingerland, chief executive officer, Convergent Genomics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.